首页> 外文期刊>Blood: The Journal of the American Society of Hematology >The PRDX2 gene is transcriptionally silenced and de novo methylated in Hodgkin and Reed-Stern berg cells of classical Hodgkin lymphoma
【24h】

The PRDX2 gene is transcriptionally silenced and de novo methylated in Hodgkin and Reed-Stern berg cells of classical Hodgkin lymphoma

机译:PRDX2基因在经典霍奇金淋巴瘤的霍奇金和里德-斯特恩伯格细胞中被转录沉默并从头甲基化

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In a recent issue of Blood, Agrawal-Singh et al reported the identification of PRDX2 (peroxiredoxin 2) as a novel tumor suppressor gene in acute myeloid leukemia (AML). The authors observed recurrent histone H3 deacetylation and DNA hypermethylation at the PRDX2 promoter region in primary leukemia samples. Epigenetic alterations correlated with low expression of PRDX2 protein and were associated with poor prognosis in AML patients. Moreover, the authors demonstrated that this gene acts as a growth inhibitor in myeloid cells. Here, we provide evidence that PRDX2 methylation and transcriptional silencing is recurrent not only in AML but also in classical Hodgkin lymphoma (cHL), further emphasizing the importance of loss of this tumor suppressor in hematologic malignancies.
机译:在最近一期的《血液》中,Agrawal-Singh等人报道了PRDX2(过氧化物酶2)的鉴定为急性髓细胞性白血病(AML)中的新型肿瘤抑制基因。作者观察到原发性白血病样本中PRDX2启动子区域的组蛋白H3脱乙酰化和DNA超甲基化。表观遗传学改变与PRDX2蛋白的低表达有关,并与AML患者的预后不良有关。而且,作者证明了该基因在髓样细胞中起生长抑制剂的作用。在这里,我们提供的证据表明PRDX2甲基化和转录沉默不仅在AML中复发,而且在经典霍奇金淋巴瘤(cHL)中也复发,进一步强调了在血液恶性肿瘤中这种肿瘤抑制子的丢失的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号